Clinical Trials Browser

Nasopharyngeal Carcinoma × durvalumab × Clear all

NCT04231864 2020-10-26

Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer

Phase 2 Withdrawn

Nasopharyngeal Carcinoma

NCT04447612 2020-06-25

Concurrent Chemoradiation and Durvalumab for Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 2 Unknown

Nasopharyngeal Carcinoma